Elsevier

Brain Research

Volume 756, Issues 1–2, 9 May 1997, Pages 256-265
Brain Research

Research report
Brain microsomal metabolism of phencyclidine in male and female rats

https://doi.org/10.1016/S0006-8993(97)00203-5Get rights and content

Abstract

These studies examined the microsomal brain metabolism of phencyclidine (PCP) in male and female Sprague–Dawley rats. Several monohydroxylated metabolites of PCP were detected including cis- and trans-1-(1-phenyl-4-hydroxycyclohexyl)piperidine (c-PPC and t-PPC) and 1-(1-phenylcyclohexyl)-4-hydroxypiperidine (PCHP). The in vitro formation of these metabolites required NADPH and was inhibited by carbon monoxide. c-PPC was formed in the male and female brain microsomes at rates of 7.1±1.3 and 5.7±1.1 fmol/min per mg, respectively, while t-PPC was formed at rates of 16.2±3.3 and 16.5±4.2 fmol/min per mg. PCHP had the highest formation rate at 50.7±8.9 and 48.2±8.8 fmol/min per mg, respectively. Although previous studies with rat liver microsomes find higher levels of PCP metabolism in male rats and the formation of an irreversibly bound metabolite in male rats, the present study of brain metabolism found no sex differences in brain metabolism. The formation of PCP metabolites in male rat livers is at least partially mediated by the male-specific isozyme CYP2C11, and possibly CYP2D1. Nevertheless, the formation of the major brain metabolite, PCHP, was not inhibited by an anti-CYP2C11 or an anti-CYP2D6 antibody. However, PCHP formation was inhibited by drug inhibitors of CYP2D1-mediated metabolism, suggesting the involvement of a CYP2D isoform. These data indicate brain metabolism of PCP is significant, but unlike the liver it is not sexually dimorphic.

Introduction

Phencyclidine (PCP) is a psychotomimetic agent that exerts its pharmacological effects at several sites within the central nervous system (CNS). Among these sites are the PCP receptor which is a binding site in the ion channel associated with the N-methyl-d-aspartate (NMDA) receptor complex 25, 44, 53, and the dopamine transporter which is inhibited by PCP 9, 43. Although the CNS plays a key role in mediating PCP effects, its role in metabolism of PCP is not known.

Metabolism is the major mechanism for termination of the pharmacological effects of PCP 16, 26, however mammalian metabolism of PCP has mostly been studied in liver and lung tissue (for review see [17]). These studies show PCP metabolism leads to the formation of a monohydroxylated metabolite of PCP (1-(1-phenylcyclohexyl)-4-hydroxypiperidine, PCHP) that has about one-third the pharmacological potency of PCP [10]. In addition, PCP metabolism in these tissues leads to in vitro and in vivo irreversible binding of a PCP metabolite 13, 23, 24, 52. Direct toxicity and/or pharmacological effects of this metabolite are not known. Nevertheless, it has been postulated that if highly reactive PCP metabolites were formed in the human brain, it could play a role in the long-lasting PCP induced psychotic behavior which is sometimes observed 14, 23.

Although several enzyme systems are responsible for PCP metabolism, the cytochrome P450 (CYP) system is of major importance [17]. Law 23, 24reports that pretreatment of rats with PCP results in a significant decrease in benzo(a)pyrene hydroxylase activity. This substrate is associated with CYP1A1 activity (previously known as P-450c) [37]. Phenobarbital induction of liver metabolism suggests the involvement of the phenobarbital-inducible CYP isoforms in PCP metabolism 8, 20, 35and irreversible binding in the liver 13, 14, 20. Studies from Owens et al. [33]and Hiratsuka et al. [12]suggest a possible role for CYP2D isoforms in the formation of PCP metabolites. These investigators 12, 39also find that CYP2C11 (a male-specific CYP isoform [19]) is a major enzyme responsible for PCP metabolism and irreversible binding in normal male rat livers.

Although immunochemical and reverse transcriptase-polymerase chain reaction techniques have demonstrated the presence of multiple CYP forms in the brain (e.g. 21, 38, 45, 47), relatively few studies have examined the role of these enzymes in the formation of metabolites of xenobiotics. Furthermore, PCP and/or PCP metabolites persist in rat brain for up to 3 weeks following a single dose [27]and brain concentrations of PCP are significantly higher than serum concentrations at all times after intravenous PCP administration in male Sprague–Dawley (SD) rats [42]. Perrin et al. [35]suggest that PCP can interact with the active site of CYP enzymes in the brain since PCP causes a type I spectral modification when incubated with rat brain mitochondrial or microsomal fractions. Another study [51]shows that a PCP-derived tetrahydropyridinium metabolite is formed in the presence of rat brain mitochondria.

Although these studies suggest PCP can be metabolized by the brain, the results are unclear. Therefore, the purpose of these studies was to examine the metabolism of PCP in rat brain microsomes. Since previous studies find sexually dimorphic PCP-induced behavior [28], neurotoxicity [30]and liver metabolism 28, 32, 39, we examined in vitro PCP metabolism in male and female rat brain homogenates.

Section snippets

Materials

Phencyclidine hydrochloride (PCP), cis-1-(1-phenyl-4-hydroxycyclohexyl)piperidine (c-PPC), trans-(1-phenyl-4-hydroxycyclohexyl)piperidine (t-PPC), 1-(1-phenylcyclohexyl)-4-hydroxypiperidine (PCHP), 5-[N-(1′-phenylcyclohexyl)amino]pentanoic acid (PCHAP), and 1-(1-[phenyl-3-3H(n)]cyclohexyl)piperidine ([3H]PCP, 15.69 Ci/mmol labeled at a metabolically stable site) were obtained from the National Institute on Drug Abuse (Rockville, MD). All other chemicals were obtained from Fisher Scientific

Characteristics of rat brain microsomal protein

For each pool of five rat brains, approximately 40 mg of microsomal protein was recovered. We attempted to measure the total CYP content by the methods described by Omura and Sato [31]and the more sensitive method for brain microsomes described by Ghersi-Egea et al. [11]; but, we were unable to determine the cytochrome P450 content of these preparations due to the low levels of CYP and a high spectral background (results not shown). Nevertheless, a study by Perrin et al. [36]reports equal

Discussion

These studies examined the in vitro metabolism of PCP by male and female rat brain microsomes. We detected the formation of several major metabolites of PCP in brain that are also formed in rat liver (Table 1). These PCP metabolites were all monohydroxylated metabolites (c-PPC, t-PPC and PCHP) (Fig. 1). The formation of these metabolites was time, protein and NADP+ dependent (Fig. 2, Fig. 3, Fig. 4). The highly polar amino pentanoic acid metabolite (PCHAP) was not detected. This metabolite is

Acknowledgements

This work was supported by a grant from the National Institute on Drug Abuse (DA04136), a Research Scientist Development Award to S.M.O. (K02 DA00110), and a predoctoral fellowship to E.M.L. (T32 DA07260). We wish to thank Dr. H.V. Gelboin for his generous gift of the anti-CYP2C11 monoclonal antibody and Dr. L.M. Arnold for the control monoclonal antibody. Shannon L. Sorrels and Melinda Gunnell also provided helpful technical assistance and advice. A preliminary report of these studies was

References (54)

  • Anandatheerthavarada, H.K., Shanker, S.K. and Ravindranath, V., Rat brain cytochromes P-450: catalytic, immunochemical...
  • Barbeau, A., Roy, M., Paris, S., Cloutier, T., Plasse, L. and Poirier, J., Ecogenetics of Parkinson's disease:...
  • Bartsch, H., Margison, G.P., Malaveille, C., Camus, A.M., Brun, G. and Margison, J.M., Some aspects of metabolic...
  • Brosen, K., Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics, Clin....
  • Buckpitt, A.R. and Warren, D.L., Evidence for hepatic formation, export and covalent binding of reactive napthalene...
  • Burke, M.D., Thompson, S., Elcombe, C.R., Halpert, J., Haaparanta, T. and Mayer, R.T., Ethoxy-, pentoxy-, and...
  • Caporaso, N.E. and Shaw, G.L., Clinical implications of the competitive inhibition of the debrisoquine-metabolizing...
  • Chaturvedi, A.K., Rao, N.G.S. and Berg, I.E., The role of hepatic microsomal enzymes in the modulation of...
  • Chaudieu, I., Vignon, J., Chicheportiche, M., Kamenka, J.-M., Trouiller, G. and Chicheportiche, R., Role of an aromatic...
  • Cone, E.J., Vaupel, D.B. and Yousefnejad, D., Monohydroxy metabolites of phencyclidine (PCP): Activities and urinary...
  • Ghersi-Egea, J.-F., Walther, B., Minn, A. and Siest, G., Quantitative measurement of cerebral cytochrome P-450 by...
  • Hiratsuka, A., Chu, T.Y.Y., Distefano, E.W., Lin, L.Y., Schmitz, D.A. and Cho, A.K., Inactivation of constitutive...
  • Hoag, M.K.P., Trevor, A.J., Asscher, Y., Weissman, J. and Castagnoli, Jr., N., Metabolism dependent inactivation of...
  • Hoag, M.K.P., Trevor, A.J., Kalir, A. and Castagnoli, Jr., N., Phencyclidine iminium ion: NADPH-dependent metabolism,...
  • Hodgson, A.V., White, T.B., White, J.W. and Strobel, H.W., Expression analysis of the mixed function oxidase system in...
  • Holsztynska, E.J. and Domino, E.F., Biotransformation is a major mechanism for terminating the action of phencyclidine...
  • Holsztynska, E.J. and Domino, E.F., Biotransformation of phencyclidine, Drug Met. Rev., 16 (1985–86)...
  • Jayyosi, Z., Cooper, K.O. and Thomas, P.E., Brain cytochrome P450 and testosterone metabolism by rat brain subcellular...
  • Kamataki, T., Maeda, K., Yamazoe, Y., Nagai, T. and Kato, R., Sex difference of cytochrome P-450 in the rat:...
  • Kammerer, R.C., Schmitz, D.A., Hwa, J.J. and Cho, A.K., Induction of phencyclidine metabolism by phencyclidine,...
  • Kapitulnik, J., Gelboin, H.V., Guengerich, F.P. and Jacobowitz, D.M., Immunohistochemcial localization of cytochrome...
  • Kobayashi, S., Murray, S., Watson, D., Sesardic, D., Davies, D.S. and Boobis, A.R., The specificity of inhibition of...
  • Law, F.C.P., Metabolic disposition and irreversible binding of phencyclidine in rats, Toxicol. Appl. Pharmacol., 57...
  • Law, F.C.P. and Farquharson, T.E., Metabolism and irreversible binding of phencyclidine by rabbit lung and liver...
  • Lodge, D., Anis, N.A., Berry, S.C. and Burton, N.R., Arylcyclohexylamines selectively reduce excitation of mammalian...
  • Mayersohn, M., Owens, S.M. and Woodworth, J.R., Phencyclidine disposition in animals. In G. Barnett and C.-W.N. Chang...
  • Misra, A.L., Pontani, R.B. and Bartolomeo, J., Persistence of phencyclidine (PCP) and metabolites in brain and adipose...
  • Cited by (0)

    1

    Current address: Department of Environmental Health, School of Public Health, University of Washington, 4225 Roosevelt Way NE, #100, Seattle, WA 98105-6099, USA.

    View full text